The optimal treatment of STEMI: new pharmacological and device approaches

Panminerva Med. 2013 Dec;55(4):339-43.

Abstract

Cardiovascular disease remains the leading cause of mortality worldwide. Many deaths are contributed to acute ST elevation myocardial infarction (STEMI). Recently, epidemiological studies have been shown reduction in STEMI related mortality over the last decade. This reduction has partially been attributed to new pharmacological and device advances that were utilized during STEMI treatment. The goal of this manuscript is to review new pharmacological and device approaches available in the treatment of STEMI patients.

Publication types

  • Review

MeSH terms

  • Absorbable Implants
  • Cardiac Catheters* / trends
  • Cardiovascular Agents / adverse effects
  • Cardiovascular Agents / therapeutic use*
  • Diffusion of Innovation*
  • Drug-Eluting Stents
  • Humans
  • Myocardial Infarction / diagnosis
  • Myocardial Infarction / mortality
  • Myocardial Infarction / therapy*
  • Percutaneous Coronary Intervention / adverse effects
  • Percutaneous Coronary Intervention / instrumentation*
  • Percutaneous Coronary Intervention / mortality
  • Percutaneous Coronary Intervention / trends
  • Prosthesis Design
  • Stents* / trends
  • Thrombectomy / adverse effects
  • Thrombectomy / instrumentation*
  • Thrombectomy / mortality
  • Thrombectomy / trends
  • Treatment Outcome

Substances

  • Cardiovascular Agents